GALAPAGOS NV (GLPG.AS) Stock Fundamental Analysis
Europe - AMS:GLPG - BE0003818359 - Common Stock
27.5 EUR
+0.36 (+1.33%)
GLPG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. While GLPG seems to be doing ok healthwise, there are quite some concerns on its profitability. GLPG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GLPG has reported negative net income.
GLPG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
GLPG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of GLPG (-7.45%) is better than 64.86% of its industry peers.
GLPG's Return On Equity of -10.75% is fine compared to the rest of the industry. GLPG outperforms 71.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.45% | ||
| ROE | -10.75% | ||
| ROIC | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLPG's Profit Margin has improved in the last couple of years.
GLPG has a better Gross Margin (87.59%) than 79.73% of its industry peers.
In the last couple of years the Gross Margin of GLPG has declined.
GLPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
The number of shares outstanding for GLPG has been increased compared to 5 years ago.
GLPG has a worse debt/assets ratio than last year.
2.2 Solvency
GLPG has an Altman-Z score of 1.46. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
GLPG's Altman-Z score of 1.46 is fine compared to the rest of the industry. GLPG outperforms 64.86% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GLPG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, GLPG belongs to the top of the industry, outperforming 87.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.46 |
ROIC/WACCN/A
WACC7.88%
2.3 Liquidity
A Current Ratio of 8.08 indicates that GLPG has no problem at all paying its short term obligations.
GLPG's Current ratio of 8.08 is amongst the best of the industry. GLPG outperforms 90.54% of its industry peers.
GLPG has a Quick Ratio of 7.99. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.99, GLPG belongs to the top of the industry, outperforming 90.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.08 | ||
| Quick Ratio | 7.99 |
3. Growth
3.1 Past
GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -200.70%.
The earnings per share for GLPG have been decreasing by -12.47% on average. This is quite bad
The Revenue for GLPG has decreased by -52.50% in the past year. This is quite bad
Measured over the past years, GLPG shows a very negative growth in Revenue. The Revenue has been decreasing by -20.82% on average per year.
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%
3.2 Future
The Earnings Per Share is expected to decrease by -40.64% on average over the next years. This is quite bad
Based on estimates for the next years, GLPG will show a decrease in Revenue. The Revenue will decrease by -0.05% on average per year.
EPS Next Y-346.2%
EPS Next 2Y-84.1%
EPS Next 3Y-65.78%
EPS Next 5Y-40.64%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-4.07%
Revenue Next 5Y-0.05%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GLPG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GLPG's earnings are expected to decrease with -65.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.1%
EPS Next 3Y-65.78%
5. Dividend
5.1 Amount
No dividends for GLPG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMS:GLPG (10/31/2025, 7:00:00 PM)
27.5
+0.36 (+1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners25.23%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.81B
Revenue(TTM)275.61M
Net Income(TTM)-284274000
Analysts48.24
Price Target29.5 (7.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1378.49%
Min EPS beat(2)-1682.53%
Max EPS beat(2)-1074.45%
EPS beat(4)1
Avg EPS beat(4)-663.96%
Min EPS beat(4)-1682.53%
Max EPS beat(4)154.1%
EPS beat(8)5
Avg EPS beat(8)-142.38%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.96%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)4.35%
Revenue beat(4)1
Avg Revenue beat(4)-8.31%
Min Revenue beat(4)-15.5%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)86.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-150.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.69 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.32
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-4.52
FCFYN/A
OCF(TTM)-4.23
OCFYN/A
SpS4.18
BVpS40.12
TBVpS36.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.45% | ||
| ROE | -10.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.59% | ||
| FCFM | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30.4% | ||
| Cap/Sales | 7.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.08 | ||
| Quick Ratio | 7.99 | ||
| Altman-Z | 1.46 |
F-Score1
WACC7.88%
ROIC/WACCN/A
Cap/Depr(3y)93.66%
Cap/Depr(5y)187.37%
Cap/Sales(3y)17.05%
Cap/Sales(5y)15.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
EPS Next Y-346.2%
EPS Next 2Y-84.1%
EPS Next 3Y-65.78%
EPS Next 5Y-40.64%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-4.07%
Revenue Next 5Y-0.05%
EBIT growth 1Y-98.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.52%
EBIT Next 3Y-12.01%
EBIT Next 5Y14.78%
FCF growth 1Y45.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.13%
OCF growth 3YN/A
OCF growth 5YN/A
GALAPAGOS NV / GLPG.AS FAQ
What is the fundamental rating for GLPG stock?
ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS.
What is the valuation status of GALAPAGOS NV (GLPG.AS) stock?
ChartMill assigns a valuation rating of 0 / 10 to GALAPAGOS NV (GLPG.AS). This can be considered as Overvalued.
What is the profitability of GLPG stock?
GALAPAGOS NV (GLPG.AS) has a profitability rating of 3 / 10.
What is the financial health of GALAPAGOS NV (GLPG.AS) stock?
The financial health rating of GALAPAGOS NV (GLPG.AS) is 5 / 10.